🔥🐔 BizChicken 🐔🔥

Companies Similar to Enliven Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. logo
Market Cap: High
Employees: Lowest

small molecule kinase inhibitors

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer treatment, including key products ELVN-001 and ELVN-002 under clinical trials.

Tags: biopharmaceutical, cancer treatment, clinical-stage, kinase inhibitors, small molecule inhibitors

Symbol: ELVN

Recent Price: $22.39

Industry: Biotechnology

CEO: Mr. Samuel S. Kintz M.B.A.

Sector: Healthcare

Employees: 52

Address: 6200 Lookout Road, Boulder, CO 80301

Phone: 720 647 8519

Leadership

  • Sam Kintz, Co-founder, Chief Executive Officer, and Member of the Board of Directors
  • Joe Lyssikatos, Co-founder, Chief Scientific Officer
  • Anish Patel, Co-founder and Chief Operating Officer
  • Helen Collins, Chief Medical Officer
  • Ben Hohl, Chief Financial Officer and Head of Corporate Development
  • Galya Blachman, Chief Legal Officer and Head of Business Development
  • Rich A. Heyman, Chairman of the Board of Directors
  • Rishi Gupta, Member of the Board of Directors
  • Andy Phillips, Member of the Board of Directors
  • Mika Kakefuda Derynck, Member of the Board of Directors
  • Jake Bauer, Member of the Board of Directors
  • Rahul Ballal, Member of the Board of Directors
  • Lori Kunkel, Member of the Board of Directors
  • Brian Druker, Scientific Advisor
  • Kevin Koch, Scientific Advisor

Last updated: 2024-12-31

Cytokinetics, Incorporated

Cytokinetics, Incorporated logo
Market Cap: Highest
Employees: Medium

muscle activators and inhibitors

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors to treat debilitating diseases.

Tags: biopharmaceutical, clinical trials, drug development, muscle activators, muscle inhibitors

Symbol: CYTK

Recent Price: $47.15

Industry: Biotechnology

CEO: Mr. Robert I. Blum

Sector: Healthcare

Employees: 423

Address: 350 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 624 3000

Last updated: 2024-12-31

Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

ENHANZE drug delivery technology

Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enabling subcutaneous delivery of biologics using its patented ENHANZE technology. The company operates in the United States and internationally, offering products such as Hylenex recombinant and developing treatments for various medical conditions including lymphomas and immunodeficiency disorders.

Tags: ENHANZE, biologics, biopharma, drug delivery, technology, therapeutics

Symbol: HALO

Recent Price: $47.99

Industry: Biotechnology

CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

Sector: Healthcare

Employees: 373

Address: 11388 Sorrento Valley Road, San Diego, CA 92121

Phone: 858 794 8889

Last updated: 2024-12-31

Kronos Bio, Inc.

Kronos Bio, Inc. logo
Market Cap: Lowest
Employees: Lowest

entospletinib (ENTO)

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapeutics targeting dysregulated transcription factors. It is developing product candidates like entospletinib for acute myeloid leukemia and KB-0742 for MYC-amplified solid tumors.

Tags: acute myeloid leukemia, biopharmaceutical, cancer therapeutics, solid tumors, transcription factors

Symbol: KRON

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Norbert W. Bischofberger Ph.D.

Sector: Healthcare

Employees: 58

Address: 1300 South El Camino Real, San Mateo, CA 94402

Phone: 650 781 5200

Last updated: 2024-12-31

Ikena Oncology, Inc.

Ikena Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

IK-930

Ikena Oncology is a targeted oncology company developing medicines tailored to biomarker-defined patient groups, with a focus on unmet needs in cancer treatment.

Tags: biomarkers, biotechnology, cancer treatment, oncology, pharmaceuticals

Symbol: IKNA

Recent Price: $1.60

Industry: Biotechnology

CEO: Dr. Mark Manfredi Ph.D.

Sector: Healthcare

Employees: 18

Address: 645 Summer Street, Boston, MA 02210

Phone: 857 273 8343

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TNX-103, TNX-102 (levosimendan), TNX-201 (imatinib)

Tenax Therapeutics, Inc. is a specialty pharmaceutical company that focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases. The company is involved in developing medications such as TNX-103 and TNX-102 (levosimendan) for pulmonary hypertension and heart failure, and TNX-201 (imatinib) for pulmonary arterial hypertension.

Tags: TNX-102, TNX-103, TNX-201, cardiovascular, pharmaceutical, pulmonary diseases

Symbol: TENX

Recent Price: $6.55

Industry: Biotechnology

CEO: Mr. Christopher T. Giordano

Sector: Healthcare

Employees: 5

Address: ONE Copley Parkway, Morrisville, NC 27560

Phone: 919 855 2100

Last updated: 2024-12-31

Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

ZN-c3, ZN-c5

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for treating various cancers. Its leading product candidates include ZN-c3 and ZN-c5, which are in various phases of clinical trials targeting specific cancer types.

Tags: biopharmaceutical, cancer treatment, clinical trials, small molecule therapeutics

Symbol: ZNTL

Recent Price: $2.92

Industry: Biotechnology

CEO: Dr. Kimberly Lynn Blackwell M.D.

Sector: Healthcare

Employees: 124

Address: 1359 Broadway, New York, NY 10018

Phone: 212 433 3791

Last updated: 2024-12-31

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ALRN-6924

Aileron Therapeutics, Inc. is a clinical stage oncology company developing ALRN-6924 for various cancer treatments, with multiple clinical trials in progress.

Tags: ALRN-6924, cancer therapies, chemoprotection, clinical stage, clinical trials, oncology

Symbol: ALRN

Recent Price: $2.32

Industry: Biotechnology

CEO: Dr. James Brian Windsor Ph.D.

Sector: Healthcare

Employees: 15

Address: 285 Summer Street, Boston, MA 02210

Phone: 617 995 0900

Last updated: 2024-12-31

Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Ik T-148009

Inhibikase Therapeutics, Inc. is a clinical stage pharmaceutical company focused on developing therapeutics for Parkinson's Disease and related disorders. Their product pipeline includes treatments for neurological and cancer-related conditions.

Tags: Cancer Treatment, Neurological Disorders, Parkinson's Disease, Pharmaceutical, Therapeutics

Symbol: IKT

Recent Price: $3.24

Industry: Biotechnology

CEO: Dr. Milton H. Werner Ph.D.

Sector: Healthcare

Employees: 8

Address: 3350 Riverwood Parkway SE, Atlanta, GA 30339

Phone: 678 392 3419

Leadership

  • Milton H. Werner, Ph.D., President and CEO
  • C. Warren Olanow MD, FRCPC, FRCP (Hon.), Medical Consultant and CEO of Clintrex Research Corporation
  • Garth Lees-Rolfe, CPA, Chief Financial Officer
  • Dan Williams, Controller
  • Terence Kelly, Ph.D., Medicinal Chemistry Consultant
  • Surendra Singh, Ph.D., Chemistry and Manufacturing Controls
  • Merrill M. Kraines, Partner, McDermott, Will & Emery, Outside General Counsel
  • Roberto Bellini, Managing Partner at BSQUARED Capital
  • Dennis Berman, Serial Entrepreneur
  • David Canner, Ph.D., Partner at Soleus Capital
  • Roy Freeman, M.D., Professor of Neurology at the Harvard Medical School, Director of the Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
  • Arvind Kush, Chief Financial Officer and Chief Business Officer of Candid Therapeutics
  • Amit Munshi, Chief Executive Officer of Orna Therapeutics

Last updated: 2024-12-31

Inozyme Pharma, Inc.

Inozyme Pharma, Inc. logo
Market Cap: Medium
Employees: Lowest

INZ-701

Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.

Tags: ABCC6, ENPP1, INZ-701, biopharmaceutical, calciphylaxis, genetic diseases, mineralization, rare diseases, therapeutics

Symbol: INZY

Recent Price: $2.82

Industry: Biotechnology

CEO: Dr. Douglas A. Treco Ph.D.

Sector: Healthcare

Employees: 59

Address: 321 Summer Street, Boston, MA 02210

Phone: 857 330 4340

Leadership

  • Doug Treco, Ph.D., CEO, Chairman of Board of Directors
  • Gayle Gironda, Senior Vice President and Chief People Officer
  • Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
  • Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
  • Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
  • Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
  • Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
  • Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
  • David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
  • Sarah Bhagat, Ph.D., Director
  • Reinaldo M. Diaz, MBA, Director
  • Martin Edwards M.D., MBA, Director
  • Erik Harris, MBA, Director
  • Rob Hopfner, Rph, Ph.D., MBA, Director
  • Edward Mathers, Director
  • Lynne Sullivan, MST, Director

Last updated: 2024-12-31

Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

KPI-012, EYSUVIS, INVELTYS

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for eye diseases using proprietary mucus penetrating particles technology.

Tags: biopharmaceutical, corneal epithelial defects, dry eye disease, eye diseases, gene expression, mucus penetrating particles, ocular surgery, retinal diseases

Symbol: KALA

Recent Price: $6.87

Industry: Drug Manufacturers - Specialty & Generic

CEO: Mr. Mark T. Iwicki

Sector: Healthcare

Employees: 43

Address: 1167 Massachusetts Avenue, Arlington, MA 02476

Phone: 781 996 5252

Last updated: 2024-12-31

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated logo
Market Cap: High
Employees: Lowest

Kyprolis, Evomela, Veklury, Teriparatide, Vaxneuvance, Pneumosil, Rylaze, Nexterone, Zulresso, Noxafil-IV

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing or acquiring technologies to aid pharmaceutical companies in discovering and developing medicines. The company's commercial programs include treatments for multiple myeloma, COVID-19, osteoporosis, invasive diseases, childhood pneumonia, and acute lymphoblastic leukemia.

Tags: biopharmaceutical, commercial programs, disease treatment, medicine development, pharmaceutical technology

Symbol: LGND

Recent Price: $105.76

Industry: Biotechnology

CEO: Mr. Todd C. Davis Ph.D.

Sector: Healthcare

Employees: 58

Address: 5980 Horton Street, EmeryVille, CA 94608

Phone: 858 550 7500

Last updated: 2024-12-31

Leap Therapeutics, Inc.

Leap Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

DKN-01

Leap Therapeutics, Inc. is a biopharmaceutical company focused on acquiring and developing therapies for the treatment of cancer, with lead programs including DKN-01, targeting various cancer types through clinical trials.

Tags: DKN-01, biopharmaceutical, cancer treatment, clinical trials, oncology

Symbol: LPTX

Recent Price: $2.92

Industry: Biotechnology

CEO: Mr. Douglas E. Onsi J.D.

Sector: Healthcare

Employees: 54

Address: 47 Thorndike Street, Cambridge, MA 02141

Phone: 617 714 0360

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. logo
Market Cap: Lowest
Employees: Lowest

SON-1010, SON-080

Sonnet Bio Therapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company developing biologic medicines using its human albumin binding technology. The company is based in Princeton, New Jersey, and has lead candidates such as SON-1010 for non-small cell lung cancer, and SON-080 for neuropathies.

Tags: albumin binding technology, biologic medicines, biotechnology, interleukin 12, interleukin 6, oncology

Symbol: SONN

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Pankaj Mohan Ph.D.

Sector: Healthcare

Employees: 12

Address: 100 Overlook Center, Princeton, NJ 08540

Phone: 609-375-2227

Leadership

  • Pankaj Mohan, Ph.D., Founder, CEO & Chairman
  • Jay Cross, Chief Financial Officer
  • John K. Cini, Ph.D., Chief Scientific Officer & Co-Founder
  • Susan Dexter, Chief Technical Officer
  • Richard Kenney, M.D., Chief Medical Officer
  • Albert Dyrness, Board Member
  • Nailesh Bhatt, Chief Executive Officer & Board Member
  • Raghu Rao, Board Member
  • Donald Griffith, Financial Controller
  • Lori McNeill, Board Member

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

Viking Therapeutics, Inc.

Viking Therapeutics, Inc. logo
Market Cap: Highest
Employees: Lowest

VK2809

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead drug candidate VK2809 in Phase IIb trials for non-alcoholic steatohepatitis.

Tags: VK2809, biopharmaceutical, clinical-stage, endocrine disorders, metabolic disorders, therapies

Symbol: VKTX

Recent Price: $39.77

Industry: Biotechnology

CEO: Dr. Brian Lian Ph.D.

Sector: Healthcare

Employees: 30

Address: 9920 Pacific Heights Boulevard, San Diego, CA 92121

Phone: 858 704 4660

Leadership

  • Lawson Macartney, DVM, Ph.D., Chairman
  • Matthew W. Foehr, Chief Executive Officer
  • Kathy Rouan, Ph.D.,
  • Charles A. Rowland Jr.,
  • Matthew Singleton,
  • Brian Lian, Ph.D.,

Last updated: 2024-12-31

Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

N/A

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.

Tags: SARS-Co V-2, biotechnology, hepatitis B virus, liver diseases, pharmaceuticals, respiratory syncytial virus, small molecule drugs, viral infections

Symbol: ENTA

Recent Price: $5.85

Industry: Biotechnology

CEO: Dr. Jay R. Luly Ph.D.

Sector: Healthcare

Employees: 145

Address: 500 Arsenal Street, Watertown, MA 02472

Phone: 617 607 0800

Leadership

  • Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
  • Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
  • Matthew P. Kowalsky, J.D., Chief Legal Officer
  • Brendan Luu, Chief Business Officer
  • Paul J. Mellett, Chief Financial and Administrative Officer
  • Yat Sun Or, Ph.D., Chief Scientific Officer
  • Scott T. Rottinghaus, M.D., Chief Medical Officer
  • Bruce L.A. Carter, Ph.D., Chairman of the Board
  • Mark G. Foletta, Board Member
  • Yujiro S. Hata, Board Member
  • Kristine Peterson, Board Member
  • Lesley Russell, MBChB, MRCPb, Board Member
  • Terry Vance, Board Member

Last updated: 2024-12-31